GILD decided two years ago not to advance GS9190 + SoC to phase-3
Do you really think GILD intends to use this drug in oral testing as stated in the PR? What value could GS9190 add to an oral combo when it wasn't worth pursuing alone with SOC? Now the issue with SAE's and potential clinical holds put on other classes of drugs in the pipeline participating in oral combo studies. I guess it's hard to admit when your lead HCV compound sucks.
Market Data 
Markets 
AI
